key: cord-0751331-u3du0h9c
authors: Tang, Julian W.; Bialasiewicz, Seweryn; Dwyer, Dominic E.; Dilcher, Meik; Tellier, Raymond; Taylor, Janette; Hua, Harry; Jennings, Lance; Kok, Jen; Levy, Avram; Smith, David; Barr, Ian G.; Sullivan, Sheena G.
title: Where have all the viruses gone? Disappearance of seasonal respiratory viruses during the COVID‐19 pandemic
date: 2021-04-06
journal: J Med Virol
DOI: 10.1002/jmv.26964
sha: 98218cd881eb004b0f748946edf4fb4d231e8c8f
doc_id: 751331
cord_uid: u3du0h9c

Many viruses cause seasonal respiratory infections in temperate climates that peak in the winter months. They cause varying degrees of respiratory illness across all age groups, and include respiratory syncytial virus (RSV), parainfluenza viruses (types 1-4), human metapneumovirus, rhinoviruses, seasonal coronaviruses (OC43, 229E, NL63, HKU1), enteroviruses, adenoviruses and influenza viruses. This results in a significant healthcare burden across all populations with now well-established seasonality patterns. We now have good evidence that the spread of most seasonal respiratory viruses has been severely curtailed in Australia, New Zealand, and other Southern hemisphere populations including Chile and South Africa, believed to be attributable to the COVID-19 restrictions. A similar pattern is now being observed in the UK and Europe with minimal influenza and RSV activity during the 2020/21 northern hemisphere winter season, and most influenza-like illness (ILI) consultations being COVID-19-related. This article offers some additional data and a possible explanation on this phenomenon This article is protected by copyright. All rights reserved.

Where have all the viruses gone? Disappearance of seasonal respiratory viruses during the COVID-19 pandemic Many viruses cause seasonal respiratory infections in temperate climates that peak in the winter months. They cause varying degrees of respiratory illness across all age groups and include respiratory syncytial virus (RSV), parainfluenza viruses (types 1-4), human metapneumovirus, rhinoviruses, seasonal coronaviruses (OC43, 229E, NL63, HKU1), enteroviruses, adenoviruses, and influenza viruses.

This results in a significant healthcare burden across all populations with now well-established seasonality patterns. 1 We now have good evidence that the spread of most seasonal respiratory viruses has been severely curtailed in Australia, 2 New Zealand, 3 One possible answer is that we have achieved some degree of herd immunity to these pre-existing seasonal respiratory viruses, to which we now require a higher exposure dose before developing successful infection and disease. Such pre-existing immunity may increase the exposure dose required for successful reinfection and/ or disease. 8 Although we do not yet know the infectious dose for SARS-CoV-2, one estimate, based on older animal studies with SARS-CoV-1 suggests that just 200-300 viruses are needed to cause successful infection in 50% of an exposed population. 9 In human patients, one study demonstrated that thousands of SARS-CoV-2 RNA copies may be exhaled each minute by a patient in the acute phase of COVID-19, 10 potentially expelling tens of infectious doses into the surrounding air that could infect susceptible people nearby. In the absence of specific, pre-existing immunity, the infectious dose for SARS-CoV-2 is likely to be lower than for the seasonal respiratory viruses, against which most of us will have some degree of immunity.

More recently, with the easing of COVID-19 restrictions, some parts of Australia have been experiencing high levels of RSV activity ( Figure 1 ). These RSV peaks are occurring later than any previous seasonal RSV activity, which suggests that the COVID-19 prevention measures may have simply delayed the epidemics of some of these viruses, with subsequent reappearance when measures are relaxed beyond a certain level.

Clearly, we do not yet fully understand the drivers for the very unusual patterns of activity of our normally relatively predictable winter respiratory viruses. Nevertheless, the massive reduction in the incidence of influenza and other seasonal respiratory viruses during this COVID-19 pandemic has been a welcome respite. These viruses usually cause considerable morbidity and mortality, 11, 12 which could be exacerbated if cocirculating with COVID-19. For example, data from the 2019-2020 winter in the United Kingdom suggested that SARS-CoV-2/influenza coinfections resulted in more severe disease outcomes (https://www.medrxiv.org/content/10. 1101/2020.09.18.20189647v2#disqus_thread).

This will allow resources to be reallocated to coping with the COVID-19 cases being admitted to the hospital throughout the remainder of this winter season, and demonstrates an incidental benefit (a "silver lining") of such restrictions, despite their general unpopularity.

Yet, we do need to be prepared for a possible resurgence of the other seasonal respiratory viruses such as RSV (and potentially influenza), as COVID-19 restrictions are eased going into the UK Spring/Summer seasons, particularly as the new COVID-19 vaccines are rolled-out more widely, and that this resurgence may not follow the usual seasonal patterns.

Global epidemiology of noninfluenza RNA respiratory viruses: data gaps and a growing need for surveillance

Where has all the influenza gone? The impact of COVID-19 on the circulation of influenza and other respiratory viruses

Impact of the COVID-19 nonpharmaceutical interventions on influenza and other respiratory viral infections in New Zealand

Decreased influenza activity during the COVID-19 pandemic-United States

Weekly national Influenza and COVID19 surveillance report: Week 49 report (up to week 48 data) 3 December 2020

European Centre for Disease Prevention and Control. COVID-19 situation update for the EU/EEA and the UK, as of 9

Ranking the effectiveness of worldwide COVID-19 government interventions

Covid-19: Do many people have pre-existing immunity?

COVID-19: A Risk Assessment Perspective

Coronavirus disease 2019 patients in earlier stages exhaled millions of severe acute respiratory syndrome coronavirus 2 per hour

Estimates of global seasonal influenza-associated respiratory mortality: a modelling study

Determining the burden of respiratory syncytial virus disease: the known and the unknown